Bone mineral (Hydroxyapatite) (HA)

Bone mineral, primarily composed of hydroxyapatite [Ca10(PO4)6(OH)2], serves as a critical pharmacological target in conditions characterized by abnormal bone remodeling [1]. In areas of high bone turnover, such as those affected by osteoporosis, Paget's disease, or metastatic bone cancer, the mineral surface is more accessible and metabolically active, providing a site for drug accumulation [2]. Therapeutic agents like bisphosphonates exploit this by binding to the hydroxyapatite crystals with high affinity, subsequently inhibiting osteoclast activity and reducing bone resorption [3, 5]. Additionally, radiopharmaceuticals like Radium-223 dichloride act as calcium mimetics, utilizing the high turnover of bone mineral to localize therapeutic isotopes to skeletal lesions [4]. This targeting mechanism is essential for stabilizing bone density and managing skeletal-related events in oncological and metabolic bone diseases [5].

Other names

HydroxyapatiteBone matrixCalcium phosphate mineralCrystalline bone mineralSkeletal mineral

Drugs targeting bone mineral typically utilize high-affinity adsorption to hydroxyapatite crystals, particularly at sites of active remodeling, to either inhibit bone-resorbing cells or deliver localized radiation [2, 3, 4].